Valneva的Chikungunya疫苗显示95%的剂量后4年有效,没有安全问题和所有年龄的持久保护。 Valneva's chikungunya vaccine shows 95% effectiveness four years post-dose, with no safety issues and lasting protection across all ages.

根据VLA1553-303试验的长期数据,Valneva的Chikungunya疫苗IXCHI在一次剂量后四年保持95%的血清反应率,所有年龄组,包括65岁及65岁以上的成年人,都保留了抗体的中和性保护。 Valneva's chikungunya vaccine IXCHIQ® maintained a 95% seroresponse rate four years after a single dose, with neutralizing antibodies remaining protective in all age groups, including adults 65 and older, according to long-term data from the VLA1553-303 trial. 通过两年的后续行动,没有报告新的安全关切。 No new safety concerns were reported through two years of follow-up. 疫苗的耐久免疫反应支持其防止蚊虫传染疾病爆发的潜力。 自2013年以来,蚊虫传染疾病已蔓延到110多个国家,在美洲造成370多万例病例。 The vaccine’s durable immune response supports its potential to prevent outbreaks of the mosquito-borne disease, which has spread to over 110 countries and caused over 3.7 million cases in the Americas since 2013. 该公司计划监测抗体持久性达10年之久,并通过与CEPI和印度血清研究所的伙伴关系扩大全球准入。 The company plans to monitor antibody persistence for up to ten years and is expanding global access through partnerships with CEPI and the Serum Institute of India.